semaglutide novo nordisk rolls out $349 Wegovy cash price ahead of plan Here's Novo Nordisk's First Oral

Over a mean follow-up period of 39.8 months, semaglutide demonstrated superiority over placebo in reducing the composite endpoint of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke among overweight or obese patients with established cardiovascular disease, but without diabetes

Of these, only 82 completed a food record, and only 70 completed all three days

Prepared to accept your brightest self

As fat cells shrink under the influence of GLP-1 medications, they release stored contents into the surrounding tissue

My rebuttal to that concern comes from the SELECT trial testing Wegovy in patients with heart disease